IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26FDA’s decision follows ...

IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26 FDA's decision follows positive Phase 1 results for GT-02287 in both healthy ...

A woman’s health journey is shaped by a series of significant life transitions, each bringing unique physical, emotional, and ...

Analysts have good things to say about these shares. Let's find out why. The post Why these ASX shares could rise 20% to 30% ...

The S&P/ASX Healthcare Index is showing signs of recovery, rising 13.31% in June 2026 and up so far in July after hefty falls ...

Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data, and Interaxon Inc.(Muse) today ...

Axsome Therapeutics (NASDAQ: AXSM) and Revolution Medicines (NASDAQ: RVMD) have offered investors significant growth so far ...

Emerging research reveals GLP-1 drugs like Ozempic may combat diseases beyond obesity, including cancer and addiction, though ...

Researchers are exploring drugs like Ozempic, Mounjaro, and Wegovy to treat or prevent a range of conditions, including ...

Eli Lilly Canada Inc. (Lilly Canada) has officially received a long-awaited positive recommendation (reimbursement with conditions) from Canada's Drug Agency (CDA-AMC) for its medicine, Ebglyss®, for ...

A recently published case report in Frontiers in Neuroscience details how a high dose of psilocybin mushrooms appeared to temporarily restore specific daily functions and communication abilities in an ...

For many of us, shoulder pain is an inevitable part of reaching middle age. More than two-thirds of UK adults will develop ...